Cyclomics raises €2.6 million to advance liquid biopsy diagnostics | Alumni news (Venture Challenge Fall 2017)

Cyclomics, alumnus of the Venture Challenge Fall 2017, has raised €2.6 million in new financing to support the further development and commercialisation of its liquid biopsy diagnostics for cancer detection.

The investment round was led by Myosotis Investments, with participation from new and existing investors. The funding strengthens Cyclomics’ position as it moves from an R&D focused organisation towards a more commercial phase.

Cyclomics is developing diagnostic tests based on its CyclomicsSeq technology, which amplifies circulating tumour DNA to enable the detection of cancer related mutations at very low frequencies. The technology is designed to improve the sensitivity and accuracy of liquid biopsy based cancer diagnostics.

With the new funding, Cyclomics aims to progress towards regulatory approvals in Europe and the United States. This includes preparations for CE-IVD certification for its Epinn software platform, as well as steps towards US FDA clearance for its diagnostic assays.

The company was founded in 2018 as a spin off from UMC Utrecht and focuses on bringing its liquid biopsy solutions closer to clinical application, supporting earlier and more precise cancer classification.

Source: Cyclomics